There seems to be an increasing degree of acknowledgement in the medical literature that these lower limb amputations are drug-class side effects of SGLT2 inhibitors class diabetes medicines such as Jardiance and Farxiga in addition to Invokana. For example, from this recent Medscape news report, “Canagliflozin (Invokana) Gets FDA Nod for CV … [Read more...]
J&J Tries to Expand Invokana Label to Include Cardiovascular Benefits
Johnson & Johnson's, the drug manufacturer of diabetes drugs Invokana, Invokamet, and Invokamet XR, recently submitted a supplemental new drug application (sNDA) to the FDA to request expansion of the labels for these drugs. If granted, the new label would include a cardiovascular indication concerning the reduction of risk of cardiovascular … [Read more...]